Universität zu Köln

Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2022). Treatment of early stage favorable and unfavorable Hodgkin lymphoma. Onkologie, 28 (10). S. 879 - 889. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Full text not available from this repository.

Abstract

Background In early stage classical Hodgkin lymphoma (cHL), reduction of treatment-associated toxicity while maintaining achieved high cure rate remains a major goal. Objectives Evidence-based development of current treatment recommendations for early stage favorable and unfavorable HL. Methods Evaluation of current randomized trials, meta-analyses, and relevant retrospective analyses with regard to tumor control, overall survival, and safety data. Results and conclusions Two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and 20 Gy involved-site radiotherapy (IS-RT) are still regarded as standard in early stage favorable HL and are also used in the older patients, unless there are contraindications. Compared to standard treatment, the (18F)fluorodeoxyglucose (FDG) positron emission tomography (PET)-based RT-approach resulted in significantly lower tumor control in the RAPID, H10, and HD16 trials and can therefore only be considered as an individual approach after weighing the benefits and risks of long-term toxicity of RT. In early stage unfavorable HL, two cycles of (escalated(e))BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) followed by two cycles of ABVD (2 + 2) result in significantly higher progression-free survival (PFS) compared to four cycles of ABVD. The HD17 trial showed that 2 + 2 additionally enables a PET-guided RT-approach without impairment of tumor control, i.e., omission of RT in those patients with negative PET after 2 + 2. Therefore, 2 + 2 + PET-guided RT is recommended as the new standard in patients <= 60 years of age. In patients older than 60 years, combined modality treatment (CMT) with two cycles of ABVD followed by two cycles of AVD and 30 Gy IS-RT is still recommended.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sasse, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Momotow, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Broeckelmann, P. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Baues, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eich, H. T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-674247
DOI:	10.1007/s00761-022-01228-2
Journal or Publication Title:	Onkologie
Volume:	28
Number:	10
Page Range:	S. 879 - 889
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	2731-7234
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EXTENDED-FIELD RADIOTHERAPY; TERM-FOLLOW-UP; OLDER PATIENTS; OPEN-LABEL; CHEMOTHERAPY; THERAPY; TRIAL; MULTICENTER; DACARBAZINE; BLEOMYCIN Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67424